At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 37 enrolled
Drug / intervention
AzaSite (azithromycin ophthalmic solution) +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Single-Center, Open-Label, Randomized Study of the Pharmacokinetics of AzaSite Ophthalmic Solution Versus Vigamox in the Tears of Healthy Volunteers Following a Single Ocular Administration
In Brief
A Phase 4 clinical trial evaluating AzaSite (azithromycin ophthalmic solution) and Vigamox (moxifloxacin hydrochloride ophthalmic solution) for Bacterial Infections and Eye Infections. Completed, enrolled 37 participants across 1 site.
Detailed Summary
The purpose of this study is to evaluate the drug concentrations of AzaSite compared to Vigamox in tears of healthy volunteers
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBacterial Infections, Eye Infections
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedDec 2007
Enrollment StartMar 2008
Primary CompletionOct 2008
TodayJul 2026
First PostedDec 18, 2007
Enrollment StartMar 1, 2008
Primary CompletionOct 1, 2008
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 18.5 years ago
Interventions
AzaSite (azithromycin ophthalmic solution)drug
One drop ophthalmic solution at Visit 2
Vigamox (moxifloxacin hydrochloride ophthalmic solution)drug
One drop ophthalmic solution at Visit 2